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1. Introduction 
The chapter addresses similar biological medicinal products (biosimilars) safety monitoring 
and describes the activities that should be developed in their risk minimisation plan. This is 
an issue that has aroused great interest with the recent expiration of biotech drugs patents 
and the advent of biosimilar products on the market. 
2. Risk management 
A medicinal product is authorised on the basis that in the specified indication(s), at the time 
of authorisation, the risk-benefit is judged positive for the target population. However, not 
all actual or potential risks will have been identified when an initial authorisation is sought. 
In addition, there may be subsets of patients for whom the risk is greater than that for the 
target population as a whole. 
The management of a single risk can be considered as having four steps, risk detection, risk 
assessment, risk minimisation and risk communication which are summarized at table 1. 
However, a typical individual medicinal product will have multiple risks attached to it and 
individual risks will vary in terms of severity, and individual patient and public health 
impact. Therefore, the concept of risk management should also consider the combination of 
information on multiple risks with the aim of ensuring that the benefits exceed the risks by 
the greatest possible margin both for the individual patient and at the population level. 
Meanwhile Table 1 explains the management of a single risk, Figure 1 goes further and 
describes a complete risk management system, the so-called “Risk Management Plan” (EU-
RMP) which contains two parts: pharmacovigilance and risk minimization. It covers how the 
safety of a product will be monitored and measured to reduce risk. 
This chapter focuses on the activities that should be developed in the risk minimisation plan 
to be applied to biopharmaceuticals and more specifically to biosimilars (medicines similar 
but not identical to a biological medicine approved once patent lifetime for the original 
biotherapeutic has expired). Biopharmaceuticals often exhibit safety issues such as 
immunotoxicity that may lead to a loss of efficacy and/or to side effects (Giezen et al., 2009; 
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Stanulovic et al., 2011). The CHMP guidelines on biosimilars states that data from pre-
authorisation clinical studies normally are insufficient to identify all potential differences 
with the reference product (Giezen et al., 2008). The main regulatory basis related to risk 
management are listed on Table 2. 
 
DIFFERENT STEPS OF RISK MANAGEMENT 
RISK DETECTION 
AND ASSESSMENT 
Identify the risks Preclinical studies 
Harms identified in clinical trials & 
meta-analyses 
Formal mortality and morbidity studies 
Understand the risk Rigorous case definition 
Case series analysis 
Clear description in label 
Monitor the risk Post marketing surveillance 
Database analyses 
Prospective cohort studies and registries 
(to study potentially rare but important 
risks where risk identification or 
product attribution is difficult) 
RISK 
MINIMISATION 
AND 
COMMUNICATION 
Communicate the risk Advice in label (not enough to 
communicate specific risk minimisation 
activities or change behaviours)  
Partnership with regulators 
Education of physicians, patients, 
company staff 
Act to reduce the risk Limited distribution 
Limited prescribing rights 
Contra-indicate for certain groups, 
indications, routes of 
administration 
Advice for high risk groups 
Measure outcome of interventions
Table 1. Risk Management steps 
 
REGULATORY FOCUS ON RISK MANAGEMENT 
ICH E2E Pharmacovigilance Planning (Nov 2004) 
EMA 
The Guideline on Risk Management Systems for Medicinal 
Products for Human Use (EMEA/CHMP/96268/2005). The 
Guideline has been included as chapter I.3 of Volume 9A. 
Annex C: Template for EU Risk Management Plan 
(EMEA/192632/2006) 
GMP ANNEX 20 Quality Risk Management (Feb 2008) 
Table 2. Risk Management Legal Framework 
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Part 
I 
1. Safety specification: 
• Summarizes important identified 
risks, and important missing 
information, and addresses 
populations potentially at risk and 
outstanding safety questions. 
• Helps identify needs for specific data 
collection and facilitates construction 
of a pharmacovigilance plan 
2. Pharmacovigilance plan: 
• Describes pharmacovigilance 
activities (routine and additional) 
and action plans for each safety 
concern 
• Proposes actions to address 
identified safety concerns, 
complementing the procedures in 
place to detect safety signals. 
•  
 
 
Part 
II 
 
4. Risk minimisation plan: 
• Lists safety concerns for which risk 
minimization activities are proposed 
• Discusses associated routine and 
additional risk minimization 
activities and the assessment of their 
effectiveness 
• Detail risk minimization activities to 
reduce risks associated with an 
individual safety concern 
 
3. Evaluation of the need for risk 
minimization activities: 
• Discusses safety concerns 
including potential for 
medication errors and the need 
for routine or additional risk 
minimization strategies 
• Assesses for each safety concern 
whether risk minimization 
strategies are needed beyond the 
pharmacovigilance action plans 
 
Fig. 1. Risk Management Plan development 
2.1 Risk identification and safety specification 
This is a summary of the important specified risks of a medicinal product, important 
potential risks, and important missing information. It also addresses the populations 
potentially at risk and outstanding safety questions, which warrant further investigation to 
refine understanding of the benefit-risk profile during the post-authorisation period. Table 3 
explains the different considerations to take in mind when collecting safety data during the 
non-clinical and clinical development of a biosimilar medicinal drugs. 
The safety issues identified in the safety specification should be based on the information 
related to the safety of the product included in the Common Technical Document (CTD), 
especially the overview of safety, benefits and risks conclusions and the summary of clinical 
safety (Zúñiga & Calvo, 2010a). The safety specification can be a stand-alone document, 
usually in conjunction with the pharmacovigilance plan, but elements can also be 
incorporated into the CTD. 
Clinical safety of similar biological medicinal products must be monitored closely on an 
ongoing basis during the post-approval phase including continued risk-benefit assessment. 
Even if the efficacy is shown to be comparable, the biosimilar product can exhibit a different 
safety profile in terms of nature, seriousness, or incidence of adverse reactions. Marketing 
Authorisation Holder (MAH) should provide safety data prior to marketing authorisation, 
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but also post-marketing as possible differences might become evident later, even though 
comparability with regard to efficacy has been shown. It is important to compare adverse 
reactions in terms of type, severity and frequency between biosimilar and reference 
medicinal product. Attention should be paid to immunogenicity and potential rare serious 
adverse events, focusing on patients with chronic treatments.  The risk management plans 
for biosimilars should focus on: 
• Heightened pharmacovigilance measures 
• Conduct antibody testing 
• Implement special post-marketing surveillance 
For the marketing authorisation application a risk management program / pharma-
covigilance plan is required. This includes a risk specification describing the possible safety 
issues caused by the differences (i.e. hostcells, manufacturing, purification, excipients etc.) of 
the biosimilar to the reference product. 
 
ELEMENTS OF THE SAFETY SPECIFICATION
Non-Clinical 
Non-clinical safety findings 
that have not been 
adequately addressed by 
clinical data 
• Toxicity 
• General pharmacology 
• Drug interactions 
• Other toxicity-related information and data 
If the product is intended for use in special populations, 
consideration should be given to wether specific non-
clinical data needs exist. 
Clinical 
Limitations of the human
safety database 
• Discussion of the implications of the database 
limitations with respect to predicting the safety of 
the product in the marketplace 
• Reference to the populations likely to be exposed 
during the intended or expected use of the product 
in medical practice. 
• Discussion of the world-wide experience: 
- The extent of the world-wide exposure 
- Any new or different safety issues identified 
- Any regulatory actions related to safety 
• Detail the size of the study population using both 
numbers of patients and patient time exposed to the 
drug. This should be stratified by relevant 
population categories. 
• Detail the frequencies of adverse drug reactions 
detectable given the size of the database. 
• Detail suspected long-term adverse reactions when it 
is unlikely that exposure data is of sufficient 
duration and latency.
Populations not studied in 
the pre-authorisation phase 
• Discussion of which populations have not been 
studied or have only been studied to a limited 
degree in the pre-authorisation phase and the 
implications of this with respect to predicting the 
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safety of the product in the marketplace:
- Children 
- The elderly 
- Pregnant or lactating women 
- Patients with relevant co-morbidity such as 
hepatic or renal disorders 
- Patients with disease severity different from that 
studied in clinical trials 
- Sub-populations carrying known and relevant 
genetic polymorphism 
- Patients of different racial and/or ethnic origins 
• Reference the relevance of inclusion and exclusion 
criteria in relation to the target population 
Adverse events/ adverse 
reactions  
The risk data should be presented according to the 
specific format described in section 3.6.2.c) of the Volume 
9A The rules governing medicinal products in the EU 
(March 2007)
• List the important identified and potential risks that 
require further characterization or evaluation 
(identified or potential risks)
Identified Risks (an untoward occurrence for which there 
is adequate evidence of an association with the medicinal 
products of interest). 
• Include more detailed information on the most 
important identified adverse events/ adverse 
reactions (serios, frequent and/or with an impact on 
the balance of benefits and risks of the medicinal 
product). 
• Include evidence bearing on a casual relationship, 
severity, seriousness, frequency, reversibility and at-
risk groups, if available. 
• Discussion of risk factors and potential mechanisms 
Potential risks (an untoward occurrence for which there is 
some basis for suspicion of an association with the 
medicinal product of interest but where this association 
has not been confirmed). 
• Description of important potential risks with the 
evidence that led to the conclusion that there was a 
such a type of risk
Identified and potential 
interactions including food-
drug and drug-drug 
interactions 
• Discussion of identified and potential 
pharmacokinetic and pharmacodynamic interactions 
• Summary of the evidence supporting the interaction 
and the possible mechanism 
• Discussion of the potential health risks posed for the 
different indications and in the different populations 
• Statement listing the interactions that require further 
investigation
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Epidemiology • Discussion of the epidemiology of the indications 
including incidence, prevalence, mortality and 
relevant co-morbidity (take into account 
stratification by age, sex and racial/ethnic origin) 
• Discussion of the epidemiology in the different 
regions with emphasis on Europe 
• Review the incidence rate of the important adverse 
events that require further investigation among 
patients in whom the medicinal product is indicated 
• Include information on risks factors for an adverse 
events
Pharmacological class effects • Identify risks believed to be common to the 
pharmacological class (justified those risks common 
to the pharmacological class but not thought to be a 
safety concern) 
Additional EU requirements • Discussion of the following topics: 
- Potential for overdose 
- Potential for transmission of infectious agents 
- Potential for misuse for illegal purposes 
- Potential for off-label use 
- Potential for off-label paediatric use
Summary 
• Important identified risks 
• Important potential risks 
• Important missing information 
Table 3. Elements of the risk identification and safety specification (EMA, 2006) 
2.2 Pharmacovigilance plan 
The pharmacovigilance plan should be based on the safety specification and propose actions 
to address the safety concerns identified (relevant identified risks, potential risks and 
missing information). An action plan model can be found on Table 4. Only a proportion of 
risks are likely to be foreseeable and the pharmacovigilance plan will not replace but rather 
complement the procedures currently used to detect safety signals. 
 
Safety concern Planned action (s) 
Important identified risks <> List 
Important potential risks <> List 
Important missing information <> List 
Table 4. Summary of safety concern and planned pharmacovigilance actions (EMA, 2006) 
The plan can be discussed with regulators during product development, prior to approval of 
the new product or when safety concerns arise during the post-marketing period. It can be a 
stand-alone document but elements could also be incorporated into the CTD (table 5) 
(Zúñiga & Calvo, 2010b). 
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ROUTINE PHARMACOVIGILANCE ADDITTIONAL PHARMACOVIGILANCE 
ACTIVITIES 
• For medicinal products where no 
special concerns have arisen 
• For medicinal products with important 
identified risks, important potential risks 
or important missing information 
• The activities will be different depending 
on the safety concern to be addressed 
Table 5. Pharmacovigilance activities 
The action plan for each safety concern should be presented and justified according to the 
following structure: 
• Safety concern 
• Objective of proposed actions 
• Actions proposed 
• Rationale for proposed actions 
• Monitoring by the MAH for safety concern and proposed actions 
• Milestones for evaluation and reporting 
Protocols for any formal studies should be provided. Details of the monitoring for the safety 
concern in the clinical trial will include stopping rules, information on the drug safety 
monitoring board and when interim analyses will be carried out. 
The outcome of the proposed actions will be the basis for the decision making process that 
needs to be explained in the EU-RMP. 
CHMP biosimilars guidelines emphasise need for particular attention to pharmacovigilance, 
especially to detect rare but serious side effects. 
Important issues include: 
• Pharmacovigilance systems should differenciate between originator and biosimilar 
products (so that effects of biosimilars are not lost in background of reports on reference 
products). 
• Ensure Traceability (importance of the international nonproprietary name, INN). 
2.3 Evaluation of the need for risk minimisation activities 
For each safety concern, the Applicant/Marketing Authorisation Holder should assess 
whether any risk minimisation activities are needed. Some safety concerns may be 
adequately addressed by the proposed actions in the Pharmacovigilance Plan, but for others 
the risk may be of a particular nature and seriousness that risk minimisation activities are 
needed. It is possible that the risk minimisation activities may be limited to ensuring that 
suitable warnings are included in the product information or by the careful use of labelling 
and packaging, i.e. routine risk minimisation activities. If an Applicant/Marketing 
Authorisation Holder is of the opinion that no additional risk minimisation activities 
beyond these are warranted, this should be discussed and, where appropriate, supporting 
evidence provided. 
However, for some risks, routine risk minimisation activities will not be sufficient and 
additional risk minimisation activities will be necessary. If these are required, they should be 
described in the risk minimisation plan which should be included in Part II of the EU-RMP. 
www.intechopen.com
 
Risk Management Trends 
 
258 
Within the evaluation of the need for risk minimisation activities, the Applicant/Marketing 
Authorisation Holder should also address the potential for medication errors (some 
examples are listed on Table 6) and state how this has been reduced in the final design of the 
pharmaceutical form, product information, packaging and, where appropriate, device. 
 
POTENTIAL REASONS FOR MEDICATION ERRORS 
Naming Taking into account the Guideline on the Acceptability of 
Invented Names for Human Medicinal Products Processed 
through the Centralised Procedure. CPMP/328/98 Rev 5, 
Dec 2007. 
Presentation Size, shape and colouring of the pharmaceutical form and 
packaging 
Instructions for use Regarding reconstitution, parenteral routes of 
administration, dose calculation 
Labelling 
Table 6. Potential reasons for medication errors that the applicant needs to take into account 
Applicants/Marketing Authorisation Holders should always consider the need for risk 
minimisation activities whenever the Safety Specification is updated in the light of new 
safety information on the medicinal product. 
2.4 The risk minimization plan 
The risk minimisation plan details the risk minimisation activities which will be taken to 
reduce the risks associated with an individual safety concern. When a risk minimisation 
plan is provided within an EU-RMP, the risk minimisation plan should include both routine 
and additional risk minimisation activities. A safety concern may have more than one risk 
minimisation activity attached to an objective.  
The risk minimisation plan should list the safety concerns for which risk minimisation 
activities are proposed. The risk minimisation activities, i.e. both routine and additional, 
related to that safety concern should be discussed. In addition, for each proposed additional 
risk minimisation activity, a section should be included detailing how the effectiveness of it 
as a measure to reduce risk will be assessed. Table 7 shows how to approach the risk 
minimisation plan. 
3. Postmarketing pharmacovigilance 
MAHs should ensure that all information relevant to a medicinal product´s balance of 
benefits and risks is fully and promptly reported to the Competent Authorities; for centrally 
authorised products, data also should be reported to EMA. The MAH must have a qualified 
person responsible for pharmacovigilance available permanently and continuously. 
3.1 Legal framework 
The legal framework for pharmacovigilance of medicinal products for human use in the 
European Union (EU) is given in Regulation (EC) No 726/2004 and Directive 2001/83/EC 
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(Title IX) on the Community code relating to medicinal products for human use, as last 
amended by Directive 2004/24/EC and by Directive 2004/27/EC (EudraLex, 2007). 
 
Safety concern  
Routine risk minimisation activities (i.e. 
product information, labelling and 
packaging) 
<short description of what will be put in the 
Summary of Product Characteristics (SPC), 
labelling etc to minimize risk e.g. warning in 
4.4 (special warnings and precautions for use), 
that caution should be used in patients with 
cardiac failure, etc> 
Additional risk minimisation activity 1 (e.g. 
educational material or training 
programmes for prescribers, pharmacists 
and patients, restricted access 
programmes) 
Objective and rationale 
Proposed actions  
Criteria to be used to verify the success of 
proposed risk minimisation activity 
Proposed review period 
Additional risk minimisation activity 2, etc 
Objective and rationale  
Proposed actions 
Criteria to be used to verify the success of 
proposed risk minimisation activity 
Proposed review period 
Table 7. Information required for each important identified or potential risk for which 
additional risk minimisation measures are planned 
For the biosimilar medicinal drugs approved in the Community through the centralised 
procedure, legal provisions are set forth in Regulation (EC) No. 726/2004 (Title II, Chapter 3) 
(European Commission, 2004) and Commission Regulation (EC) No. 540/95 (reporting of 
nonserious unexpected adverse reactions). The legal texts are supported by a series of 
guidelines, some of which have been compiled into Eudralex (Volume 9- 
Pharmacovigilance) (EudraLex, 2004). The requirements explained in these guidelines are 
based on the International Conference on Harmonisation (ICH) guidelines but may be 
further specified or contain additional request in line with Community legislation. 
The obligations concerned with the monitoring of adverse reactions occurring in clinical 
trials do not fall within the scope of pharmacovigilance activities. The legal framework for 
such obligations is Directive 2001/20/EC. However, Part III of Volume 9A deals with 
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technical aspects relating to adverse reaction/event reporting for pre- and post-
authorisation phases. 
Pharmacovigilance activities are within the scope of quality, safety and efficacy criteria, 
because new information is accumulated on the normal use of medicinal products in the EU 
marketplace. Pharmacovigilance obligations apply to all authorised medicinal products, 
including those authorised before 1 January 1995 (Fruijtier, 2006), whatever procedure was 
used for their authorisation. 
At approval there is limited clinical experience. Accurate pharmacovigilance and correct 
attribution of adverse events is vital. 
Pharmacovigilance has been defined by the Worl Health Organization as the science and 
activities relating to the detection, assessment, unsderstanding and prevention of adverse 
effects or any other medicine-related problem (EudraLex, 2007). 
The three main goals in Pharmacovigilance are: 
• Protect the patients 
• Protect the Pharmaceutical Company 
• Comply with regulatory Requirements 
3.2 Pharmacovigilance for centrally authorised productsreporting of adverse 
reactions and other safety-related information 
Pre-Authorisation Phase 
Once an application for a marketing authorisation is submitted to the Agency, in the pre-
authorisation phase, information relevant to the risk-benefit evaluation may become 
available from the Applicant or Member States where the product is already in use on a 
compassionate basis, or from third countries where the product is already marketed. Since it 
is essential for this information to be included in the assessment carried out by the (Co-
)Rapporteur(s) assessment teams, the Applicant is responsible for informing immediately 
the Agency and the (Co-) Rapporteur(s). 
In the period between the CHMP reaching a final Opinion and the Commission Decision 
there need to be procedures in place to deal with information relevant to the risk-benefit 
balance of centrally authorised products, which were not known at the time of the Opinion. 
It is essential for this information to be sent to the Agency and (Co-)Rapporteur(s) so that it 
can be rapidly evaluated to an agreed timetable and considered by the Committee for 
Medicinal Products for Human Use (CHMP) to assess what impact, if any, it may have on 
the Opinion. The Opinion may need to be amended as a consequence. 
Post-Authorisation Phase 
Suspected adverse reactions related to centrally authorised products are reported directly by 
Healthcare Professionals, to each Member State. Marketing Authorisation Holders report 
serious suspected adverse reactions to the Member State in which the reactions occurred, 
within 15 calendar days of receipt. Each Member State is responsible for following up the 
Individual Case Safety Reports it receives to obtain further information as necessary. 
The Member States should forward to the Agency serious suspected adverse reactions 
occurring within their territories. 
The Agency and all Member States should receive directly from the Marketing 
Authorisation Holders suspected serious and unexpected adverse reactions that occur in a 
country outside of the EU. 
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The Agency should ensure that all relevant information about suspected serious unexpected 
adverse reactions from outside the EU are entered into the EudraVigilance database, and 
Member States should ensure that data on suspected serious adverse reactions occurring in 
their territory are uploaded into the EudraVigilance database.  
Table 8 shows the main aspects to be considered relating biosimilar drugs safety during pre-
autorisation and post-authorisation phase. The table highlights the additional reporting 
requirements for biosimilars when comparing to general safety reporting.   
 
REPORTING OF ADVERSE REACTIONS AND OTHER
 SAFETY-RELATED INFORMATION 
 GENERAL REPORTING
(Scharinger, 2007)
BIOSIMILARS REPORTING 
PRE-
AUTHORISATION 
PHASE 
• All Suspected Unexpected 
Serious Adverse Reactions 
(SUSARs) 
• Sponsors to report to: 
- Concerned Member States 
(paper or electronically) 
- Concerned Ethics 
Committees (on paper) 
- EudraVigilance Trial 
Module (EVCTM) at the 
EMA (electronically) 
• Legal basis: Volume 10 of 
EudraLex- Clinical Trials 
guidelines 
• Clinical safety data always 
required, even if efficacy is 
shown to be comparable 
• Sufficient number of patients to 
compare common Adverse 
Drug Reactions (ADRs) 
between referenced and 
claimed biosimilar products 
(type, severity, frequency) 
• Risk specification and 
pharmacovigilance plan part of 
the application dossier, as per 
EU legislation and guidelines 
• Pharmacovigilance systems/ 
procedures should be in place 
(traceability as per current EU 
guidelines)
POST-
AUTHORISATION 
PHASE 
• Adverse Drug Reactions/ 
Individual Case safety Reports 
(ICSRs) 
• Electronic reporting: 
- Mandatory e-reporting of 
ICSRs 
- Definition of exceptional 
circumstances that prevent 
electronic reporting 
(mechanical, program, 
electronic or 
communication failure) 
- Fall-back procedures to 
maintain expedited 
reporting compliance are 
established 
• Periodic Safety Update Reports 
(PSURs) from MAH to the 
Competent Authorities 
• Legal basis: Volume 9A of 
EudraLex- Pharmacovigilance
• Benefit-risk assessment on an 
ongoing basis. Importance of 
clinical experience with 
biologics: 2-3 years after market 
approval to adequately validate 
risk/benefit profile. 
• Risk management programme 
may be required if rare but 
serious adverse reactions.  
Table 8. Biosimilars: pre and post-authorisation safety concerns 
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3.3 Monitoring of the safety profile 
Signal Identification 
It is likely that many potential signals will emerge in the early stages of marketing and it 
will be important for these to be effectively evaluated. 
A signal of possible unexpected hazards or changes in severity, characteristics or frequency 
of expected adverse effects may be identified by: 
• the Marketing Authorisation Holders; 
• the Rapporteur; 
• the Member States; 
• the Agency in agreement with the Rapporteur 
It is the responsibility of each Member State to identify signals from information arising in 
their territory. However, it will be important for the Rapporteur and the Agency to have the 
totality of information on serious adverse reactions occurring inside and outside the EU in 
order to have an overall view of the experience gathered with the concerned centrally 
authorised product. 
As a matter of routine, the Rapporteur should continually evaluate the adverse reactions 
included in the EudraVigilance system and all other information relevant to risk-benefit 
balance in the context of information already available on the product, to determine the 
emerging adverse reactions profile. Additional information should be requested from the 
Marketing Authorisation Holder and Member States as necessary, in liaison with the Agency. 
When a Member State other than the Rapporteur wishes to request information from the 
Marketing Authorisation Holder (apart from routine follow-up of cases occurring on their 
own territory) for the purposes of signal identification, the request should be made in 
agreement with the Rapporteur and the Agency. 
Member States will inform the Rapporteur(s) and the Agency when performing class-
reviews of safety issues which include centrally authorised products. 
The Pharmacovigilance Working Party (PhVWP) should regularly review emerging safety 
issues which will be tracked through the Drug Monitor system. 
Signal Evaluation 
As signals of possible unexpected adverse reactions or changes in the severity, 
characteristics or frequency of expected adverse reactions may emerge from many different 
sources of data (see above), the relevant information needs to be brought together for 
effective evaluation, over a time scale appropriate to the importance and likely impact of the 
signal. 
Irrespective of who identified the signal, a signal evaluation should be carried out by: 
• the Rapporteur; or 
• the Member State where a signal originated. 
The Rapporteur should work closely with the identifier of the signal to evaluate the issue. 
Agreement needs to be reached in each case on the responsibility for the Assessment Report 
on the risk-benefit balance, by the Rapporteur or the Member State where the signal 
originated from, or jointly. 
A Member State other than that of the Rapporteur should not start a full evaluation prior to 
having contacted the Agency and the Rapporteur, in order to prevent any unnecessary 
duplication of effort. 
At request of the CHMP, the PhVWP evaluates signals arising from any source and keeps 
any potential safety issues under close monitoring. 
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Evaluation of Periodic Safety Update Reports 
The Marketing Authorisation Holder is required to provide Periodic Safety Update Reports 
(PSURs) to all the Member States and the Agency. It is the responsibility of the Agency to 
ensure that the Marketing Authorisation Holder meets the deadlines. 
The Marketing Authorisation Holder should submit any consequential variations 
simultaneously with the PSUR at the time of its submission, in order to prevent any 
unnecessary duplication of effort. Variations may, however, also be requested subsequently 
by the Rapporteur, after agreement by the CHMP. 
It is the responsibility of the Rapporteur to evaluate and provide a report in accordance with 
the agreed timetable and to determine what issues if any need to be referred to the PhVWP 
and CHMP. 
Actions required following the evaluation of a PSUR will be determined by the Rapporteur 
and the Marketing Authorisation Holder will be informed by the Agency, after agreement 
by the CHMP. 
Where changes to the marketing authorisation are required, the CHMP will adopt an 
Opinion which will be forwarded to the European Commission for preparation of a 
Decision (Ebbers et al., 2010). 
Evaluation of Post-Authorisation Studies, Worldwide Literature and Other Information 
Final and interim reports of Marketing Authorisation Holder sponsored post-authorisation 
studies and any other studies, and other relevant information, may emerge from the 
Marketing Authorisation Holder, the Member States or other countries at times in between 
PSURs. 
The Rapporteur should receive and assess any relevant information and provide an 
Assessment Report where necessary. 
As above, the Rapporteur should determine what issues if any need to be referred to the 
PhVWP and CHMP. 
The actions required following an evaluation will be determined by the Rapporteur and the 
Marketing Authorisation Holder will be informed by the Agency, after agreement by the 
CHMP. 
Where changes to the marketing authorisation are required, the CHMP will adopt an Opinion 
which will be forwarded to the European Commission for preparation of a Decision. 
The Marketing Authorisation Holder should submit any consequential variations 
simultaneously with the data, in order to prevent any unnecessary duplication of effort. 
Variations may, however, also be requested subsequently by the Rapporteur, after 
agreement by the CHMP. 
Evaluation of Post-Authorisation Commitments 
It is the responsibility of the Agency to ensure that the Marketing Authorisation Holder 
meets the deadlines for the fulfilment of specific obligations and follow-up measures, and 
that the information provided is available to the Rapporteur and the CHMP. 
The Marketing Authorisation Holder should submit any consequential variations 
simultaneously with the requested information for the fulfilment of specific 
obligations/follow-up measures, in order to prevent any unnecessary duplication of effort. 
Variations may, however, also be requested subsequently by the Rapporteur, after 
agreement by the CHMP. 
For marketing authorisations granted under exceptional circumstances, specific obligations 
will be set out in Annex II.C of the CHMP Opinion. Specific obligations should be reviewed by 
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the Rapporteur, at the interval indicated in the Marketing Authorisation and at the longest 
annually, and should be subsequently agreed by the CHMP. As above, the Rapporteur should 
determine what issues if any need to be referred to the PhVWP and CHMP. 
For marketing authorisations granted under exceptional circumstances, the annual review 
will include a re-assessment of the risk-benefit balance. The annual review will in all cases 
lead to the adoption of an Opinion which will be forwarded to the European Commission 
for preparation of a Decision. 
For all marketing authorisations (whether or not the authorisation is granted under 
exceptional circumstances) follow-up measures may be established, which are annexed to 
the CHMP Assessment Report. These will be reviewed by the Rapporteur, and will be 
considered by PhVWP and CHMP at the Rapporteur’s request. 
Where changes to the marketing authorisation are required, the CHMP will adopt an Opinion 
which will be forwarded to the European Commission for preparation of a Decision. 
In the case of non-fulfilment of specific obligations or follow-up measures, the CHMP will 
have to consider the possibility of recommending a variation, suspension, or withdrawal of 
the marketing authorisation. 
Table 9 shows the  Omnitrope® Risk Management Plan Summary published by EMA. 
 
Safety issue 
Proposed pharmacovigilance
activities
Proposed risk minimisation 
activities
Diabetogenic potential 
of rhGH therapy in 
short children born 
SGA 
Phase IV prospective, single arm 
clinical trial in short children 
born SGA (part of registry 
reviewing patients’ 
demographics, long term safety 
and immunogenicity). 
Warning regarding diabetic 
potential in Section 4.4 of SPC*. 
Rare cases of type II diabetes 
mellitus in Section 4.8 of SPC. 
Occurrence and clinical 
implications of anti-
rhGH antibodies 
Phase IV prospective, single arm 
clinical trial in short children 
born SGA measuring 
immunogenicity. Prolongation 
of ongoing Phase III study 
EP2K-02-PhIIIlyo to provide 
long-term immunogenicity data 
Immunogenicity testing for 
children enrolled in registry as 
appropriate (e.g. loss of 
efficacy).
Development of antibodies 
included in Section 4.8 of SPC. 
Occurrence of 
malignancies in rhGH 
treated patients 
Registry of patients reviewing 
patients’ demographics, long 
term safety including 
malignancy and other safety 
issues.
Warning in Section 4.4 
regarding reoccurrence of 
malignancy. 
Leukaemia mentioned as a very 
rare adverse effect in Section 4.8. 
Risks of rhGH 
treatment in PWS 
patients 
Registry expected to include 
patients with PWS and will 
record demographics, long term 
safety as well as other safety 
issues in this group. 
Warnings on use of rhGH in 
PWS in Section 4.4. 
• Respiratory impairment 
and infection 
• Sleep apnoea 
• Severe obesity scoliosis 
* SPC Summary of Product Characteristics 
Table 9. Omnitrope®  Risk Management summary (EMA, 2008) 
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3.4 Handling of safety concerns 
Safety Concerns in the Pre-Authorisation Phase 
Following the receipt of Individual Case Safety Reports or other information relevant to the 
risk-benefit balance of a product by the Agency and the (Co-)Rapporteur(s), the latter 
should assess these pharmacovigilance data. The outcome of the evaluation should be 
discussed at the CHMP for consideration in the Opinion. 
If pharmacovigilance findings emerge following an Opinion but prior to the Decision, a 
revised 
Opinion, if appropriate, should be immediately forwarded to the European Commission to 
be taken into account before preparation of a Decision. 
Safety Concerns in the Post-Authorisation Phase 
A Drug Monitor, including centrally authorised products, is in place as a tracking system for 
safety concerns and is reviewed on a regular basis by the PhVWP at its meetings. This 
summary document also records relevant actions that have emerged from PSURs, specific 
obligations, follow-up measures and safety variations. 
Following the identification of a signal the relevant information needs to be brought 
together for effective evaluation, over a time scale appropriate to the importance and likely 
impact of the signal: 
• Non-urgent safety concerns 
• Urgent safety concerns 
3.5 Information to healthcare professionals and the public 
The management of the risks associated with the use of biosimilars demands close and 
effective collaboration between the key players in the field of pharmacovigilance. Sustained 
commitment to such collaboration is vital if the future challenges in pharmacovigilance are 
to be met. Those responsible must jointly anticipate, describe and respond to the continually 
increasing demands and expectations of the public, health administrators, policy officials, 
politicians and health professionals. However, there is little prospect of this happening in 
the absence of sound and comprehensive systems for biosimilars which make such 
collaboration possible. Understanding and tackling these are an essential prerequisite for 
future development of the biosimilars. 
Healthcare Professionals (and the public if applicable) need to be informed consistently in 
all Member States about safety issues relevant to centrally authorised biosimilar, in addition 
to the information provided in Product Information. If there is such a requirement the 
Rapporteur or the Marketing Authorisation Holder in cooperation with the Rapporteur 
should propose the content of information for consideration by the PhVWP and subsequent 
discussion and adoption by the CHMP. The agreed information may be distributed in 
Member States. The text and timing for release of such information should be agreed by all 
parties prior to their despatch. The Marketing Authorisation Holder should notify, at his 
own initiative, the Agency at an early stage of any information he intends to make public, in 
order to facilitate consideration by the PhVWP and adoption by the CHMP as well as 
agreement about timing for release, in accordance with the degree of urgency. Marketing 
Authorisation Holders are reminded of their legal obligations under Article 24(5) of 
Regulation (EC) No 726/2004 to not communicate information relating to pharmacovigilance 
concerns to the public without notification to the Competent Authorities/Agency (European 
Commission, 2004). 
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